Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| OTX-TP (sustained release travoprost) Intracanalicular Depot | EXPERIMENTAL | OTX-TP (sustained release travoprost) Intracanalicular Depot |
| PV (Placebo Vehicle) Intracanalicular Depot | PLACEBO_COMPARATOR | PV (Placebo Vehicle) Intracanalicular Depot |
| Name | Type | Description |
|---|---|---|
| Travoprost | DRUG | - |
| Placebo Vehicle | OTHER | - |
Inclusion Criteria: * Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or evidence of traumatic angle recession * IOP is currently controlled as assessed by the Investigator Exclusio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Travoprost is an investigational small molecule being developed for the treatment of Open Angle Glaucoma. It is delivered via an intracanalicular insert called OTX-TP, which is designed to provide sustained drug release. The drug is currently in Phase 3 clinical development for this indication.
Travoprost is a prostaglandin analog that targets the prostaglandin F2-alpha receptor. By binding to this receptor, it increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure, which is the primary goal in treating Open Angle Glaucoma.
Travoprost is being developed by Ocular Therapeutix, Inc., a biopharmaceutical company traded on NASDAQ under the ticker OCUL. The company is conducting clinical trials to evaluate the safety and efficacy of Travoprost, delivered via its proprietary OTX-TP insert, for the treatment of Open Angle Glaucoma.
Travoprost is in Phase 3 clinical development. A Phase 3 study, NCT02914509, has been completed, evaluating the safety and efficacy of OTX-TP in subjects with Open Angle Glaucoma or Ocular Hypertension. The drug is not yet approved and remains investigational.
Travoprost has one completed Phase 3 clinical trial, NCT02914509, which enrolled 565 participants with Open Angle Glaucoma or Ocular Hypertension. The study was randomized, double-blind, and placebo-controlled, conducted in the United States with participants aged 18 years and older.
Travoprost is the active pharmaceutical ingredient in OTX-TP, which is the brand name for the intracanalicular insert developed by Ocular Therapeutix. OTX-TP is designed to deliver Travoprost over an extended period to treat Open Angle Glaucoma and Ocular Hypertension.